REGN
REGENERON PHARMACEUTICALS, INC.
Nasdaq: REGN · Tarrytown, NY · Healthcare
$616.18+4.84 (+0.79%)Closed
Market Cap$58.14B
Cash$8.75Bmost recent
Runwayprofitable
P/E (TTM)14.8EPS $41.48
52-Wk Range$506.09 – $810.08
Avg Volume943.4K3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$616.18-38.0%
Pipeline

Drug candidates sponsored by REGENERON PHARMACEUTICALS · ClinicalTrials.gov

60 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Intravitreal Aflibercept Injection (IAI)
Chorioretinal Vascular Disease
Completed
2020-08-19past
1
Phase 4dupilumab
Asthma+9 more
Active, not recruiting
2027-04-24
8
Phase 4Linvoseltamab
Relapsed/Refractory Multiple Myeloma (RRMM)+4 more
Recruiting
2027-10-11
4
Phase 3rilonacept 160 mg
Familial Cold Autoinflammatory Syndrome (FCAS)+3 more
Completed
2008-06past
1
Phase 3VEGF Trap-Eye 2.0mg
Macular Edema Secondary to Central Retinal Vein Occlusion
Completed
2010-10past
1
Phase 3LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
Completed
2014-05past
1
Phase 3Intravitreal aflibercept injection [IAI]
Nonproliferative Diabetic Retinopathy
Completed
2018-08-06past
1
Phase 3Fasinumab
Chronic Low Back Pain+5 more
Completed
2020-12-01past
5
Phase 2Pozelimab
CD55-deficient Protein-losing Enteropathy+2 more
Completed
2021-11-09past
2
Phase 3Placebo
Gout+1 more
Completed
2022-01-05past
2
Phase 3casirivimab+imdevimab
Immunocompromised+3 more
Completed
2022-06-09past
3
Phase 3REGN1908-1909
Allergic Rhinitis Due to Cat Allergy+1 more
Completed
2023-01-04past
2
Phase 3evinacumab
Homozygous Familial Hypercholesterolemia+2 more
Completed
2023-04-13past
3
Phase 3Pemetrexed
Carcinoma，Non-Small-Cell Lung+3 more
Completed
2025-04-18past
1
Phase 3REGN5713
Allergic Rhinitis+2 more
Recruiting
2027-02-28
2
Phase 3Cemiplimab
Cutaneous Squamous Cell Carcinoma (CSCC)+10 more
Recruiting
2027-05-20
8
Phase 3Fianlimab
Melanoma
Active, not recruiting
2028-05-16
1
Phase 3garetosmab
Fibrodyplasia Ossificans Progressiva (FOP)+2 more
Not yet recruiting
2028-12-10
2
Phase 2REGN475/SAR164877
Back Pain
Terminated
2011-01past
1
Phase 2VEGF Trap Eye
Macular Degeneration
Completed
2011-10past
1
Phase 1REGN846
Pruritus+1 more
Terminated
2013-04past
1
Phase 2REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Homozygous Familial Hypercholesterolemia
Completed
2016-11-21past
1
Phase 2Alirocumab
Hypercholesterolemia+1 more
Completed
2016-12-22past
1
Phase 2REGN2477
Fibrodysplasia Ossificans Progressiva
Completed
2019-09-16past
1
Phase 2REGN3500
Atopic Dermatitis+3 more
Completed
2020-03-13past
3
Phase 2aflibercept
Neovascular (Wet) Age-Related Macular Degeneration
Completed
2021-05-14past
1
Phase 2SDREGN2810
Advanced Non-Small Cell Lung Carcinoma
Terminated
2021-10-27past
1
Phase 2CMP-001
Squamous Cell Carcinoma of Head and Neck+5 more
Completed
2024-02-05past
3
Phase 2REGN9933
Venous Thromboembolism+1 more
Completed
2024-05-27past
2
Phase 2REGN5381
Uncontrolled Hypertension+1 more
Completed
2025-10-15past
2
Phase 2REGN7544
Postural Orthostatic Tachycardia Syndrome (POTS)+1 more
Active, not recruiting
2026-04-13past
2
Phase 2Trevogrumab-Part A
Obesity
Active, not recruiting
2026-05-18past
1
Phase 1ALN-CIDEB
Metabolic Dysfunction-Associated Steatotic Liver Disease+2 more
Recruiting
2027-05-15
2
Phase 1ALN-PNP
Healthy Volunteers+1 more
Recruiting
2027-08-10
2
Phase 2REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Recruiting
2028-01-24
1
Phase 2ALN-HSD
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Recruiting
2028-04-27
1
Phase 2FDC fianlimab+cemiplimab
Head and Neck Squamous Cell Carcinoma (HNSCC)
Recruiting
2028-06-04
1
Phase 1REGN7041
Active Noninfectious Uveitis Affecting the Posterior Segment
Active, not recruiting
2028-06-28
1
Phase 1REGN4336
Metastatic Castration-resistant Prostate Cancer
Recruiting
2030-03-28
1
Phase 2R475
Thermal Injury Pain
Withdrawn—1
Phase 1ziv-aflibercept
Cancer
Completed
2008-05past
2
Phase 1REGN727
Healthy
Completed
2010-10past
1
Phase 1REGN1154 or placebo
Healthy Volunteers
Completed
2013-01past
1
Phase 1REGN1033 (SAR391786)
Healthy Volunteers
Completed
2014-06past
1
Phase 1REGN2176-3
Neovascular Wet Age-related Macular Degeneration (AMD)
Completed
2014-12past
1
Phase 1REGN1193
Healthy Volunteers
Completed
2015-01past
1
Phase 1REGN910-3
Neovascular Age-Related Macular Degeneration+1 more
Completed
2015-10past
1
Phase 1REGN2222
Healthy Volunteers
Completed
2016-09past
1
Phase 189Zr˗DFO˗REGN3504
Advanced PD-L1 Positive Malignancies
Terminated
2021-07-08past
1
Phase 1REGN10933+REGN10987
Healthy+1 more
Completed
2021-11-22past
1
Phase 1BPX-601
Metastatic Castration-resistant Prostate Cancer+1 more
Terminated
2023-03-14past
1
Phase 1Odronextamab multiple dose levels
Non-Hodgkin Lymphoma+1 more
Completed
2025-08-21past
1
Phase 1ALN-ANG3
Healthy Volunteers With Hyperlipidemia
Active, not recruiting
2026-12-04
1
Phase 1REGN20934
Overweight or Obesity
Not yet recruiting
2027-02-22
1
Phase 1REGN22044
Healthy Volunteer
Not yet recruiting
2027-05-27
1
N/AUnnamed
Relapsed/Refractory Follicular Lymphoma
Completed
2023-10-05past
1
N/ADUPIXENT®
Asthma
Completed
2026-04-27past
1
N/AUnnamed
Retinopathy of Prematurity
Active, not recruiting
2026-11-05
1
N/AREGN5458
Multiple Myeloma
Approved For Marketing—1
N/AREGN3470-3471-3479
Ebola Virus Disease
Available—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.